Replies to post #137523 on Biotech Values

[DewDiligence]

Kind of interesting that NVS passed over both the IDIX and ACHN NS5A’s…for Enanta's version.

NVS can still have IDIX’s NS5A drug if they really want it insofar as NVS has a right of first negotiation at the PoC stage on every compound in IDIX’s portfolio.

What’s more interesting to me is that Enanta is still independent.